Growth shares


The growth shares theme explores equity research and video content we have for companies that meet our growth stock criteria

UK stocks that meet the following criteria:

Latest and forecast Revenue Growth greater than 10%  |  Forecast EPS Growth greater than 10%  |  EPS 5 Year CAGR greater than 10%  |  FCF 5 Year CAGR greater than 10%


 

Growth shares


The growth shares theme explores equity research and video content we have for companies that meet our growth stock criteria

UK stocks that meet the following criteria:

Latest and forecast Revenue Growth greater than 10%  |  Forecast EPS Growth greater than 10%  |  EPS 5 Year CAGR greater than 10%  |  FCF 5 Year CAGR greater than 10%

Latest Content

CVS Group

Move to strengthen the Board

CVS has moved to strengthen the Board by appointing Deborah Kemp as a Non-Executive Director from immediate effect. Deborah brings a wealth of experience of working in multi-site consumer facing businesses both from an operating, M&A and property development perspective – features which are all relevant to CVS going forward. Notably, her career has involved serving as CEO of Laurel Funerals from 2010-15, Chief Operating Officer at De Vere Hotels & Resorts from 2009-10 and a lengthy period at Punch Taverns plc culminating in being the MD of the leased business. Since 2015 she has been a director of Vennco Limited, a consultancy specialising in consumer businesses and in September 2017 became interim CEO of private equity backed Synseal Group. Overall, we view this as a positive appointment in light of CVS’s rapid growth in recent years and as it looks to move to the next phase of development. Following this appointment the Board of CVS now comprises two Executive Directors and two independent Non-Executives and a Non-Executive Chairman. We continue to be positive on CVS and see the recent share price weakness as a rare buying opportunity into a structural growth story. We anticipate LFL sales newsflow to improve in 2018 as it laps softer comps and self-help measures kick in. This is an important catalyst. Fundamentally the veterinary industry is attractive and CVS is very well positioned to capitalise on its leading market position and service/geographic diversity to double earnings over the next 5 years. We see a cal’18 P/E of 22x (ex further consolidation) as attractive and argue for fair value >1300p on a 12m view.

  • 02 Jan 18
  • -
  • -

Real-time access to the latest equity research, for the first time.

📑🔎📊📈

Historically, Private Investors have had access to significantly less professional investment research and information than institutions, funds, and banks. At Research Tree, we're trying level that playing field by aggregating the latest equity research & video content from over 400 analysts at 34 City brokerages and research houses in one platform. 

 

Our goal is simple: provide retail and non-institutional investors with full access to the latest valuations, target prices, analysis, and financial models on the companies they care about, in real-time.

 

Our Partners

🏛

Research Tree aggregates the latest equity research from over 400 analysts at 34 City brokerages and research houses in one platform, giving users full access to the latest valuations, target prices, analysis, and financial models on the companies they care about, in real-time.